I never have used weight loss drugs to lose weight. I was blessed with a healthy pregnancy and gained very little during my pregnancy," Blanchard told PEOPLE ...

International Community Health Services (ICHS) has launched Together We Rise, a wellness podcast with useful information ...

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

Most people know that GLP-1 receptor agonist medications like Ozempic and Wegovy can cause relatively minor side effects like ...

The ex glamour model, 46, took to her Instagram Stories from her hospital bed  on Friday and said she was 'nice and calm' moments before being wheeled to surgery ...

Oprah Winfrey recently detailed how taking weight loss drugs shifted her longtime mindset about what she described as “thin ...

A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a ...

Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying ...

In a world overwhelmed with conflicting information about weight loss, AquaSculpt emerges as a beacon of hope for those ...

Novo Nordisk's (NVO) stock was up more than 12% in pre-market trading Friday on news the company's latest weight loss product ...

Novo Nordisk A/S soared the most since August 2023 after an experimental shot delivered as much as 22% weight loss in an early-stage trial, boosting investors’ hopes for the drugmaker’s pipeline.

The trial tested amycretin in its injectable form, but Novo Nordisk is also separately developing the drug in pill form. Investors cheered an early trial of the pill early last year that showed weight ...